The global Optogenetics Actuators and Sensors market was valued at $ 546 million in 2021 and is expected to reach $3081.17 million by 2030 expanding at a CAGR of 2.1% from 2022 to 2030.
Optogenetics is a technique for controlling neural activity using optically triggered proteins. It is a new advancement in neuroscience that offers therapeutic possibilities for incurable disorders such as retinal diseases, Parkinson's disease, and Alzheimer's disease. Optogenetic methods allow for highly precise spatial, temporal, and neurochemical activation or inhibition of particular neurons. A gene that codes for a light-sensitive protein is extracted from algal species using this approach. The gene that codes for this protein is introduced into a particular neuron in the brain and expressed, resulting in the production of this light-sensitive protein. The neural signal is transmitted when a flashing light is shone on a specific brain cell. This method may be used to regulate neuron mobility and gain a better understanding of how brain cells work at the molecular level.
The major factors that are driving the growth of the optogenetics actuators and sensors market include an increase in the prevalence of retinal diseases and neurological disorders among populations all over the world, extensive development and research in the field of optogenetics, and initiatives taken by the government in the form of financial support.
The increasing use of this sophisticated method contributes to a better understanding of the biochemical and physiological pathway that is responsible for the cause of a specific disease, as well as the identification of an accurate treatment option for that disease. This is accomplished by flashing blue light on particular neural cells.
An increasing number of research and development activities to improve the treatment for specific diseases, an increase in the population of elderly people, a surge in investment by both the private and public sectors, and an increase in the amount spent on healthcare all have a positive impact on the market for optogenetics actuators and sensors.
The United States of America led the rest of the world in terms of market share, which North America generally held. The dominance of this area may be ascribed to a number of different aspects, some of which include the local presence of market participants, ongoing research and development, technological breakthroughs, and a well-established healthcare framework in the region.
In addition, financing from both public and private institutions is a significant component that is propelling the industry in North America. Research into Parkinson's disease received a recent investment of around 107 million US dollars from the National Institute of Neurological Disorders and Strokes (NINDS), which is a component of the National Institutes of Health (NIH). In addition, the organization is launching a variety of projects, such as the Parkinson's Disease Biomarkers Programs (PDBP), a research and discovery-oriented effort, with the goal of lowering the prevalence of neurodegenerative and mental diseases in the area.
It is anticipated that Asia Pacific would be the category with the highest growth rate due to the emergence of new economies in the area as well as a rise in the amount spent on R&D. Additionally, it is envisaged that the creation of money would be fueled through cooperation across companies. The participation of the area in a variety of conferences and seminars is another factor that is expected to boost market growth.
Elliot Scientific Ltd., Gensight Biologics, Thorlabs, Inc., Addgene, The Jackson Laboratory, Coherent, Inc., and Bruker are some of the major market players. Other major market players include Scientifica (Judges Scientific Plc Company), Noldus Information Technology, Prizmatix, Danaher, Merck KGaA, Shanghai Laser & Optics Century Co., Ltd. (SLOC), AGTC, and Circuit Therapeutics, Inc.
Circuit Therapeutics, Inc. worked together on a project with the pharmaceutical business Boehringer Ingelheim, which is situated in Germany. Circuits Therapeutics, Inc. shall, in accordance with the terms of the agreement, deliver its optogenetic technology platform for the purpose of identifying and characterizing novel therapeutic targets derived from brain circuits. The mission of the firm is to create innovative treatments for the treatment of mental diseases. It is anticipated that this connection will propel technical advancements in the relevant industry.
LabCentral is a research resource and lab space supplier for companies and individual entrepreneurs located in the United States. Merck KGaA has announced that they would be collaborating with LabCentral. It is anticipated that the company would provide sponsorship for new businesses at LabCentral and eventually speed up research in the field of life science. In the next years, it is anticipated that these types of collaborations will encourage an increase in the study and development of innovative medicines for neurological illnesses.
North America
Europe
Asia Pacific
Latin America
The Middle East and Africa (MEA)